Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 62 of 108 for:    CALCIUM CATION

Change in Free 25(OH)D After High Dose in Vitamin D Deficient Postmenopausal Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02553044
Recruitment Status : Completed
First Posted : September 17, 2015
Last Update Posted : February 15, 2019
Sponsor:
Collaborator:
National Osteoporosis Society
Information provided by (Responsible Party):
Sheffield Teaching Hospitals NHS Foundation Trust

Brief Summary:

Total 25(OH)D is currently used as a biomarker of vitamin D status. However, there is some debate as to whether total 25(OH)D is the best marker to use.

It has been suggested that free vitamin D may be better because it may be more biologically available.

There are also some uncertainties about how we treat vitamin D deficiency. A single dose is attractive because it is certain that the patient has had the dose and there is no requirement for ongoing compliance, but it is still not clear what the best dose is to give. Also, recent studies have highlighted that high dose vitamin D supplementation may increase the risk of falling in older populations.

The investigators believe that studying how free vitamin D responds to different bolus doses is the best way address some of the current research gaps, including what is the best biomarker of vitamin D status, what is the mechanism of vitamin D toxicity and what is a safe bolus dose to treat deficiency.

The investigators will study changes in total and free 25(OH)D, and also clinical response, to three different bolus doses of vitamin D (50 000IU, 150 000IU and 500 000IU) in 84 vitamin D deficient postmenopausal women, over a three month period with 5 study visits. A concurrent control group of 28 vitamin D sufficient postmenopausal women will also be recruited.

This will allow the investigators to determine how total and free vitamin D change with bolus dosing and whether there is a disproportionate rise in free 25(OH)D with higher doses that may lead to hypercalcemia and falls.


Condition or disease Intervention/treatment Phase
Vitamin D Deficiency Osteoporosis Dietary Supplement: Cholecalciferol (Vitamin D3) Not Applicable

Detailed Description:

The most commonly used measurement of vitamin D status is serum 25-hydroxyvitamin D (25(OH)D). However there is no clear consensus on the level of 25(OH)D required to protect against adverse effects of deficiency.

One approach is to define deficiency is the level of 25(OH)D at which there is a secondary physiological response, such as a rise in parathyroid hormone. However, this approach has not yielded a clear answer. Total 25(OH)D below 30nmol/l is not always associated with an increased parathyroid hormone (PTH) response, and total 25(OH)D and PTH do not always respond to vitamin D supplementation. This suggests that total 25(OH)D measurement may not be the best biological marker of vitamin D status.

Vitamin D and its metabolites are bound to proteins in the circulation: around 85-90% of 25(OH)D is bound to vitamin D binding protein (DBP), 10-15% is bound to albumin, and less than 1% is in the free form. DBP protects 25(OH)D from degradation and allows a circulating store to accumulate.

The free hormone hypothesis suggests that only the unbound 'free' portion of protein bound hormones is biologically active, and that this should be measured for the accurate assessment of hormone availability. Calculated free 25(OH)D concentrations have been shown to be better correlated to bone mineral density (BMD) than total 25(OH)D in a healthy population and to be more closely related to PTH in patients with end stage renal disease.

The binding capacity of DBP may be overwhelmed in some situations. In female participants treated with an oral dose of 500,000 IU annually for 3 years there was an increase in the risk of falls and fractures that was particularly marked in the three month period after each dose. It has been proposed that there was vitamin D toxicity and possible hypercalcaemia during this period due to the binding capacity of DBP being overwhelmed by the large increase in 25(OH)D with a relatively greater increase in free 25(OH)D. However, free vitamin D and calcium were not measured in the study, so there is not yet evidence to support this hypothesis.

The investigators will study changes in total and free 25(OH)D, and clinical response to three different bolus doses of vitamin D (50,000 units, 150,000 units and 500,000 units) in 84 vitamin D deficient (<30nmol/l) postmenopausal women over three months. This will allow the investigators to determine how free and total 25(OH)D change with bolus dosing and whether there is a disproportionately high rise in free 25(OH)D with higher doses. This will also generate a better understanding of what the optimum bolus dose for treatment of vitamin D deficiency is and whether free 25(OH)D may be a better marker of vitamin D status in some situations.

Aims of the study:

  • To determine the effect of three different vitamin D bolus doses on free 25(OH)D and total 25(OH)D in vitamin D deficient post-menopausal women.
  • To determine the effect of different vitamin D bolus doses on parameters of calcium metabolism, bone turnover markers and physical function in vitamin D deficient post-menopausal women.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 112 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Change in Free 25(OH)D After High Dose in Vitamin D Deficient Postmenopausal Women
Study Start Date : October 2015
Actual Primary Completion Date : August 2018
Actual Study Completion Date : August 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 50 000IU Vitamin D3
50 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
Dietary Supplement: Cholecalciferol (Vitamin D3)
Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
Other Name: Invita D3

Experimental: 150 000IU Vitamin D3
150 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
Dietary Supplement: Cholecalciferol (Vitamin D3)
Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
Other Name: Invita D3

Experimental: 500 000IU Vitamin D3
500 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
Dietary Supplement: Cholecalciferol (Vitamin D3)
Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
Other Name: Invita D3

No Intervention: Concurrent Control
Control group to receive no intervention.



Primary Outcome Measures :
  1. Free 25(OH)D [ Time Frame: Baseline to visit 3 (5-7 days after administration) ]
    Change in free 25(OH)D from baseline to visit 3 (5-7 days after administration)


Secondary Outcome Measures :
  1. Proportion of total 25(OH)D to free 25(OH)D [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between-group difference in proportion of serum free 25(OH)D to total 25(OH)D at 5, 28 days and 84 days

  2. 1, 25(OH)2D [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between-group difference in 1, 25(OH)2D at 5, 28 days and 84 days

  3. Ionized calcium [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between-group difference in ionized calcium at 5, 28 days and 84 days

  4. Parathyroid Hormone [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between-group difference in PTH at 5, 28 days and 84 days

  5. Bone turnover marker - Alkaline Phosphatase [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between group difference in alkaline phosphatase at 5, 28 and 84 days

  6. Bone turnover marker - CTX [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between group difference in CTX at 5, 28 and 84 days

  7. Bone turnover marker - PINP [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between group difference in PINP at 5, 28 and 84 days

  8. Bone turnover marker - Osteocalcin [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between group difference in Osteocalcin at 5, 28 and 84 days

  9. Repeated chair stand test score [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between group difference in repeated chair stand test score at 5, 28 and 84 days

  10. Tandem stand balance test score [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between group difference in tandem stand balance test score at 5, 28 and 84 days

  11. 8-feet walk course test score [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between group difference in 8-feet walk course test score at 5, 28 and 84 days

  12. Laying blood pressure [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between group difference in laying blood pressure at 5, 28 and 84 days

  13. Standing blood pressure [ Time Frame: 5(+/-2) days, 28(+/-3) days and 84(+/-5) days ]
    Between group difference in standing blood pressure at 5, 28 and 84 days



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Caucasian
  • 25(OH)D < 30nmol/l for treatment groups or 25(OH)D >50nmol/l for control group
  • BMI between 20 kg/m2 and 30kg/m2
  • 55 years and over and postmenopausal (at least 5 years since last menstrual period)
  • Able and willing to participate in the study and provide written informed consent.

Exclusion Criteria:

  • History of any long term immobilization (duration greater than three months)
  • Pre-diagnosed diabetes mellitus
  • High trauma fracture or low trauma fracture less than one year prior to recruitment
  • History of or current conditions known to affect vitamin D or bone metabolism, including:

Chronic renal disease Malabsorption syndromes Diagnosed endocrine disorders Hypercalcaemia Diagnosed restrictive eating disorder

  • Use of medications or treatment known to affect vitamin D or bone metabolism such as bisphosphonates or anti-epileptic medication.
  • Alcohol intake of greater than 21 units per week
  • Holiday with significant sunlight exposure in the last six weeks
  • Planned sun holiday within study period
  • Abnormal clinical laboratory parameters that are assessed as clinically significant by the PI.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02553044


Locations
Layout table for location information
United Kingdom
Clinical Research Facility
Sheffield, South Yorkshire, United Kingdom, S5 7AU
Sponsors and Collaborators
Sheffield Teaching Hospitals NHS Foundation Trust
National Osteoporosis Society
Investigators
Layout table for investigator information
Principal Investigator: Jennifer Walsh, MBChB, PhD University of Sheffield

Publications:
Layout table for additonal information
Responsible Party: Sheffield Teaching Hospitals NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT02553044     History of Changes
Other Study ID Numbers: STH18850
First Posted: September 17, 2015    Key Record Dates
Last Update Posted: February 15, 2019
Last Verified: February 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Calcium-Regulating Hormones and Agents
Osteoporosis
Vitamin D Deficiency
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders
Vitamin D
Ergocalciferols
Cholecalciferol
Vitamins
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents